top of page
The Only CDK4 & CDK6 Inhibitor Approved Across HR+, HER2 - MBC
Wed, Dec 12
|Joey's Bar & Grill
Verzenio is indicated for the treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2- negative (HER2-) advanced or metastatic breast cancer (MBC)
Registration is Closed
See other events
Time & Location
Dec 12, 2018, 5:30 PM
Joey's Bar & Grill, 344 Chandler St, Worcester, MA 01602, USA
Guests
About The Event
Speaker:
Blanca Ledezema, APN, APNP, MN, MS, NP
UCLA Hematology Oncology Santa Monica, CA
Description:
This program will present efficacy and safety data for Verzenio, a CDK4 + CDK6 inhibitor approved in comibination with fluvestrant, in combination with an Al, and as a single age for HR+, HER2- advanced or MMBC. Information about mechanism of action and dosing will also be presented.
Program Objectives:
bottom of page